News Image

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

Provided By GlobeNewswire

Last update: May 16, 2024

BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the first quarter ended March 31, 2024 and highlighted recent developments.

Read more at globenewswire.com

INHIBIKASE THERAPEUTICS INC

NASDAQ:IKT (2/21/2025, 9:26:24 PM)

After market: 2.83 -0.14 (-4.71%)

2.97

-0.29 (-8.9%)



Find more stocks in the Stock Screener

Follow ChartMill for more